Full Cycle
Biotechnological Company
More than 20 years of experience in the development, production and sales of biomedical drugs
Full Cycle Biotechnological Company
More than 20 years of experience in the development, production and sales of biomedical drugs
About us
Welcome to our website, where we are dedicated to providing comprehensive solutions for the introduction, localization, and legalization of medical drugs.
General info
Mission
History
At PHARMAPARK, we understand the complexities and challenges faced by individuals and organizations in navigating the landscape of medical drugs. Our team is here to support you throughout the entire process, offering expertise and guidance to solve a wide range of tasks and issues.
As one of the leading players in the biopharmaceutical industry in Russia, PHARMAPARK’s development strategy is centered around the creation and production of high-quality medications through biotechnology. We are committed to bringing both generic and original (brand name) medicines to the market, ensuring access to effective treatments for a wide range of health conditions.
We take immense pride in the quality and efficacy of our products, which are the result of rigorous research, development, and testing. Our commitment to excellence extends beyond borders, as our PHARMAPARK developments are protected by international and Russian patents. This ensures the integrity of our intellectual property and reinforces our position as a trusted and respected industry leader.
At PHARMAPARK our mission is to ensure that every individual facing debilitating diseases such as breast cancer, kidney cancer, lung cancer, colorectal cancer, hepatitis B and C, nephrology, anemia, nephroid tumors, psoriasis, rheumatoid arthritis, spondylitis, and paroxysmal nocturnal hemoglobinuria has access to the most effective and safe drugs available to combat their conditions.

We are driven by a relentless commitment to research, development, testing, and improvement, drawing upon the expertise and experience of leading global institutions and companies. Our aim is to create advanced biological drugs and cutting-edge technologies for mass production within Russia.
By harnessing the power of innovation and collaboration, we serve our shareholders, investors, partners, and, most importantly, our clients, who trust in the dedication and efforts of the entire PHARMAPARK team. Together, we save lives and contribute significantly to advancing the level of healthcare in our country, enhancing the quality of life for each patient.

Every day, we strive to bring new and effective drugs to the Russian Federation market, ensuring accessibility in every city and region. Our unwavering commitment drives us forward as we work tirelessly to make a positive impact on the lives of individuals and transform the healthcare landscape in Russia.
Join us in our mission as we combine expertise, compassion, and determination to empower patients, foster medical advancements, and create a healthier future for all.
2001
Company was founded
2003
Launch of the production complex on area of 2,500 m2
2004
First production line (prokaryotic) is prepared for the production of the first batch
2005
Obtained GMP certificate
2005
Registered the first product (interferon substance)
2005
Launch of the second production line (eukaryotic)
2006
Start of production of the first finished dosage form (Altevir)
2011
Signing of the cooperation agreement with Center of Genetic Engineering and Biotechnology of Cuba
2012
Opening of R&D center on area of 1000 sq m
2012
First product registered (Interferon substance)
2013
Launch of an additional production plant on area of 1000 sq m
2013
Walvax cooperation agreement signed
2015
Monoclonal Antibodies production line prepared and launched
2021
Beginning of cooperation with BIO-THERA (China) on localization and registration of medical drugs: GOLIMUMAB and USTEKINUMAB
2020
Participation in the development of a scalable industrial technology for the production of the Sputnik V vaccine
2019
Cooperation agreement signed with Prestige Biopharma (South Korea)
2018
Mabxience S.A. signed an agreement on localization of Rituximab
2001
2005
2012
2016
2023
Our services
Our highly experienced team is thrilled to provide the following services
R&D - Research and Development
At PHARMAPARK, we offer a comprehensive range of services that encompass the full cycle of development for biological medicines.
Registration (Legalization)
Production
Organization and launch of scalable serial production for various forms of medical products:
Marketing and Sales
Development of packaging, promotion and sale of registered drugs. Participation in tenders and public procurement.
Pipeline
Pipeline
Product
Altevir
Interferon alfa-2b
Phase 1
Phase 2
Phase 3
Additional Application:
Hairy-cell leukemia, chronic myeloid leukemia, non-Hodgkin's lymphoma, melanoma, Kaposi's sarcoma accompanied by AIDS, progressive kidney cancer.
Primary Application:
Viral hepatitis B without signs of liver cirrhosis, Viral hepatitis C without signs of liver failure.
Inhouse product
Pegaltevir
Peginterferon alfa-2b
Phase 1
Phase 2
Phase 3
Inhouse product
Primary Application:
Chronic viral hepatitis B and C
Epostim
Epoetin beta
Phase 1
Phase 2
Phase 3
Inhouse product
Primary Application:
Nephrology, anemia, nephroid tumors
Additional Application:
Chemotherapy
Granogen
Filgrastim
Phase 1
Phase 2
Phase 3
Primary Application:
Chemotherapy
Inhouse product
Epodarba
Darbopoetin alfa
Phase 1
Phase 2
Phase 3
Primary Application:
Anemia in adults and children with chronic renal failure
Additional Application:
Anemia in Adult Patients with Non-Myeloid Malignancies going through chemotherapy.
Inhouse product
Infliximab
Infliximab
Phase 1
Phase 2
Phase 3
Primary Application:
Rheumatoid Arthritis
Additional Application:
Crohn's disease, psoriasis
Inhouse product
Trastusumab
Trastusumab
Phase 1
Phase 2
Phase 3
Primary Application:
Breast Cancer
Additional Application:
Advanced adenocarcinoma of the stomach or esophagogastric junction
In cooperation with Prestige Biopharma
Adalimumab
Adalimumab
Phase 1
Phase 2
Phase 3
Primary Application:
Active rheumatoid arthritis, active ankylosing spondylitis, psoriatic arthritis
Additional Application:
Chronic plaque psoriasis, active purulent hidradenitis, Crohn's disease, ulcerative colitis, non-infectious uveitis, Behçet's disease
Inhouse product
Eculisumab
Eculisumab
Phase 1
Phase 2
Phase 3
Primary Application:
Paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome
Inhouse product
Bevatsizumab
Bevatsizumab
Phase 1
Phase 2
Phase 3
Primary Application:
Colorectal cancer, non-squamous non-small cell lung cancer
Additional Application:
Glioblastoma, epithelial ovarian, fallopian tube and primary peritoneal cancer
In cooperation with Prestige Biopharma
Ustekinumab
Ustekinumab
Phase 1
Phase 2
Phase 3
Primary Application:
Plaque psoriasis, active psoriatic arthritis
In cooperation with
Bio-Thera
Golimumab
Golimumab
Phase 1
Phase 2
Phase 3
Primary Application:
Active rheumatoid arthritis, spondylitis
In cooperation with
Bio-Thera
Aflibercept
Aflibercept
Phase 1
Phase 2
Phase 3
Primary Application:
-
In cooperation with
Bio-Thera
Sekukinumab
Sekukinumab
Phase 1
Phase 2
Phase 3
Primary Application:
-
In cooperation with
Bio-Thera
OUR TEAM
At PHARMAPARK, we firmly believe that our greatest resource is people - our employees, our team.
They are the driving force behind our success, passionately committed to achieving our goals and objectives on a daily basis. Together, we constantly evolve, develop, and grow alongside the company.
Our management team comprises seasoned professionals with a wealth of experience ranging from 10 to 25 years in the field. Their expertise and in-depth knowledge enable us to tackle any challenge in the development, production, and distribution of biological preparations and substances.

Join us on our journey as we continue to build a dynamic and talented team focused on making a meaningful impact in the biopharmaceutical industry. Together, we will drive innovation, advance healthcare, and shape a better future for all.
Company Management
Vyacheslav Lebedyanskiy
CEO
Anastasia Smirnova
Executive Director
Yuriy Seregin
R&D Director
Galina Sherbinina
Quality Director
Evgeniy Arshutkin
Technical Director
Margarita Aleksandrova
Сhief technologist
Olga Erina
Logistics Director
Pavel Grigoriev
Director of Development
Our Facilities
Own production facilities, warehouse complex and research center
Production Area
R&D Center
Warehouse